Open Access
Volume 19, Number 3, August 2012
Page(s) 249 - 257
Published online 15 August 2012
  1. Allison A.C. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology, 2002, 47, 63–83. [CrossRef] [Google Scholar]
  2. Araújo F., Slifer T. & Kim S. Chronic infection with Toxoplasma gondii does not prevent acute disease or colonization of the brain with tissue cysts following reinfection with different strains of the parasite. The Journal of Parasitology, 1997, 83, 521–522. [CrossRef] [PubMed] [Google Scholar]
  3. Barragan A. & Sibley L.D. Transepithelial migration of Toxoplasma gondii is linked to parasite motility and virulence. The Journal of Experimental Medicine, 2002, 195, 1625–1633. [CrossRef] [PubMed] [Google Scholar]
  4. Brandão G.P., Ferreira A.M., Melo M.N. & Vitor R.W.A. Characterization of Toxoplasma gondii from domestic animals from Minas Gerais, Brazil. Parasite, 2006, 13, 143–149. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Brandão G.P., Melo M.N., Caetano B.C., Carneiro C.M., Silva L.A. & Vitor R.W.A. Susceptibility to reinfection in C57BL/6 mice with recombinant strains of Toxoplasma gondii. Experimental Parasitology, 2011, 128, 433–437. [CrossRef] [PubMed] [Google Scholar]
  6. Brandão G.P., Melo M.N., Gazzinelli R.T., Caetano B.C., Ferreira A.M., Silva L.A. & Vitor R.W.A. Experimental reinfection of BALB/c mice with different recombinant type I/III strains of Toxoplasma gondii: involvement of IFN-gamma and IL-10. Memórias do Instituto Oswaldo Cruz, 2009, 104, 241–245. [Google Scholar]
  7. Buzoni-Gatel D., Schulthess J., Menard L.C. & Kasper L.H. Mucosal defenses against orally acquired protozoan parasites, emphasis on Toxoplasma gondii infections. Cellular Microbiology, 2006, 8, 535–544. [CrossRef] [PubMed] [Google Scholar]
  8. Correa D., Cañedo-Solares I., Ortiz-Alegría L.B., Caballeroortega H. & Rico-Torres C.P. Congenital and acquired toxoplasmosis: diversity and role of antibodies in different compartments of the host. Parasite Immunology, 2007, 29, 651–660. [CrossRef] [PubMed] [Google Scholar]
  9. Doherty N.S. Selective effects of immunosuppressive agents against the delayed hypersensitivity response and humoral response to sheep red blood cells in mice. Agents and Actions, 1981, 11, 237–242. [CrossRef] [PubMed] [Google Scholar]
  10. Dubey J.P. Toxoplasmosis of animal and humans, 2nd edn. CRC Press: Boca Raton. 2010. [Google Scholar]
  11. Dzitko K., Staczek P., Gatkowska J. & Dlugonska H. Toxoplasma gondii: serological recognition of reinfection. Experimental Parasitology, 2006, 112, 134–137. [CrossRef] [PubMed] [Google Scholar]
  12. Elbez-Rubinstein A., Ajzenberg D., Dardé M.L., Cohen R., Dumètre A., Yera H., Gondon E., Janaud J.C. & Thulliez P. Congenital toxoplasmosis and reinfection during pregnancy: case report, strain characterization, experimental model of reinfection, and review. The Journal of Infectious Diseases, 2009, 199, 280–285. [CrossRef] [PubMed] [Google Scholar]
  13. Emadi A., Jones R.J. & Brodsky R.A. Cyclophosphamide and cancer: golden anniversary. Nature Reviews Clinical Oncology, 2009, 6, 638–647. [Google Scholar]
  14. Ferreira A.M., Vitor R.W.A., Gazzinelli R.T. & Melo M.N. Genetic analysis of natural recombinant Brazilian Toxoplasma gondii strains by multilocus PCR-RFLP. Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases, 2006, 6, 22–31. [CrossRef] [Google Scholar]
  15. Freyre A., Falcón J., Méndez J., Correa O., Morgades D. & Rodríguez A. An investigation of sterile immunity against toxoplasmosis in rats. Experimental Parasitology, 2004, 107, 14–19. [CrossRef] [PubMed] [Google Scholar]
  16. Hafizi A. & Modabber F.Z. Effect of cyclophosphamide on Toxoplasma gondii infection: reversal of the effect by passive immunization. Clinical and Experimental Immunology, 1978, 33, 389–394. [PubMed] [Google Scholar]
  17. Hassan M., Hegab M., Abaza B.E., Nasr M.E. & Mowafy N.M. Specific anti-Toxoplasma antibodies in relation to infection and reinfection using different infective stages. Journal of the Egyptian Society of Parasitology, 1999, 29, 119–129. [PubMed] [Google Scholar]
  18. Johnson L.L. & Sayles P.C. Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice. Infection Immunity, 2002, 70, 185–191. [Google Scholar]
  19. Kang H., Remington J.S. & Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-γ, TNF-α, and inducible nitric oxide synthase. Journal of Immunology, 2000, 164, 2629–2634. [Google Scholar]
  20. Khalifa A.M., Ibrahim I.R. & El-Kerdany E.D. Coccidial infection in immunosuppressed mice: prophylaxis and treatment with dehydroepiandrosterone. Eastern Mediterranean Health Journal, 2000, 6, 908–918. [Google Scholar]
  21. Lunde M.N. & Jacobs L. Antigenic differences between endozoites and cystozoites of Toxoplasma gondii. The Journal of Parasitology, 1983, 69, 806–808. [CrossRef] [PubMed] [Google Scholar]
  22. Pfaff A.W., Abou-Bacar A., Letscher-Bru V., Villard O., Senegas A., Mousli M. & Candolfi E. Cellular and molecular physiopathology of congenital toxoplasmosis: the dual role of IFN-γ. Parasitology, 2007, 134, 1895–1902. [CrossRef] [PubMed] [Google Scholar]
  23. Rollinghoff M., Starzinski-Powitz A., Pfizenmaier K. & Wagner H. Cyclophosphamide-sensitive T-lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T-lymphocytes. The Journal of Experimental Medicine, 1977, 145, 455–459. [CrossRef] [PubMed] [Google Scholar]
  24. Vidigal P.V., Santos D.V., Castro F.C., Couto J.C., Vitor R.W.A. & Brasileiro Filho G. Prenatal toxoplasmosis diagnosis from amniotic fluid by PCR. Revista da Sociedade Brasileira de Medicina Tropical, 2002, 35, 1–6. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.